Aminocaproic acid

Primary Uses

Aminocaproic acid is primarily used to treat episodes of excessive bleeding. It is often prescribed when the body's natural process of breaking down blood clots happens too quickly, leading to blood loss. This medication is commonly used in the following situations:

• Surgery: It is used during or after major surgical procedures, such as heart surgery or liver transplants, where there is a high risk of significant bleeding.
• Medical Conditions: It may be used to manage bleeding caused by certain types of cancer, including prostate, lung, or stomach cancer.
• Liver Disease: People with liver cirrhosis may experience bleeding complications that require this treatment.
• Blood Disorders: It is used for certain conditions where the body's clotting mechanism is disrupted.

Specific Bleeding Issues

This medication is also used to treat bleeding that occurs in specific areas of the body, such as the urinary tract. It helps stabilize clots to stop the loss of blood when other treatments are not sufficient. It may be administered in a hospital setting through an intravenous (IV) line or taken orally as a tablet or liquid solution.

Mechanism of Action

Aminocaproic acid belongs to a group of medications known as antifibrinolytics. Its primary function is to help the blood clot more effectively by slowing the natural process of clot breakdown.

Under normal circumstances, the body creates blood clots to stop bleeding from injuries. Once the area has healed, the body uses specific enzymes to dissolve those clots. However, in certain medical situations or after some surgeries, the body may break down these clots too fast, which can lead to dangerous or prolonged bleeding.

Aminocaproic acid works by:

• Blocking the action of substances that dissolve fibrin, which is the protein that forms the structure of a blood clot.
• Helping existing clots stay stable and intact for a longer period.

By preserving these clots, the medication helps reduce blood loss and allows the body to manage bleeding more effectively.

Common Side Effects

• Nausea or vomiting
• Stomach pain or diarrhea
• Dizziness or headache
• Tiredness or unusual weakness
• Stuffy nose or watery eyes
• Skin rash

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious symptoms:

• Unexplained muscle pain, tenderness, or weakness, especially when combined with dark-colored urine or fever
• Signs of a blood clot, such as sudden shortness of breath, chest pain, coughing up blood, or pain and swelling in the legs
• Vision changes or ringing in the ears
• Slow or irregular heartbeat
• Numbness or tingling in the arms or legs
• Seizures
• Fainting or severe lightheadedness

Blood Clotting Risks

Aminocaproic acid works by preventing the breakdown of blood clots. This mechanism can increase the risk of developing dangerous blood clots in the veins or arteries, which may lead to a heart attack, stroke, or pulmonary embolism. This medication should not be used if there is evidence of an active intravascular clotting process, such as disseminated intravascular coagulation (DIC), unless it is used in conjunction with heparin.

Muscle Damage

Prolonged use of this medication has been linked to muscle weakness and the breakdown of muscle tissue, known as rhabdomyolysis. Healthcare providers typically monitor for symptoms such as muscle pain or tenderness and may perform blood tests to check creatine phosphokinase (CPK) levels. If muscle damage is suspected, the medication is usually discontinued.

Rapid Infusion Risks

When given by injection, the medication must be infused slowly. Rapid intravenous administration has been associated with significant drops in blood pressure, slow heart rate, or abnormal heart rhythms.

Kidney and Liver Considerations

The drug is primarily excreted through the kidneys. Patients with kidney disease or impaired renal function may be at a higher risk for drug accumulation and toxicity. Caution is also advised for those with pre-existing heart or liver disease.

Neurological and Visual Effects

Some individuals may experience neurological symptoms such as dizziness, headaches, or seizures. There have also been reports of visual changes, including blurred vision or watery eyes, during treatment.

Pregnancy

It is not known whether aminocaproic acid can cause harm to an unborn baby. There have been no adequate studies in pregnant women, and animal reproduction studies have not been conducted to determine its effects on a developing fetus. Because of this lack of data, healthcare providers typically only prescribe this medication during pregnancy if the potential benefits justify the possible risks.

Breastfeeding

It is not known if aminocaproic acid passes into human breast milk or if it could affect a nursing infant. If you are breastfeeding or planning to breastfeed, you should discuss the potential risks and benefits with your healthcare provider before using this medication.

Available Forms

Aminocaproic acid is provided in the following preparations:

• Oral Tablet: A solid form taken by mouth.
• Oral Solution: A liquid form taken by mouth.
• Intravenous Injection: A liquid form administered into a vein by a healthcare professional.

FDA Approval Status

Aminocaproic acid is approved by the U.S. Food and Drug Administration (FDA) for the treatment of excessive bleeding caused by systemic hyperfibrinolysis and urinary fibrinolysis. It is available as an oral tablet, oral solution, and intravenous injection.

Approved Indications

The medication is indicated for use in clinical situations where fibrinolysis (the breakdown of blood clots) contributes to bleeding. This includes:

• Bleeding associated with heart surgery or certain cancers, such as prostate or lung cancer.
• Bleeding related to liver cirrhosis or abruptio placentae.
• Urinary tract bleeding following procedures like prostatectomy or in patients with severe kidney disease.

Regulatory Warnings

While aminocaproic acid does not have a boxed warning, the FDA-approved labeling includes several important safety precautions:

• Administration Rate: Rapid intravenous injection should be avoided, as it may lead to low blood pressure, slow heart rate, or irregular heart rhythms.
• Thrombosis Risk: Because the drug inhibits the breakdown of clots, there is a risk of unwanted blood clots. It should be used with caution in patients with pre-existing heart or vascular disease.
• Upper Urinary Tract Bleeding: The drug is generally not recommended for bleeding originating in the upper urinary tract, as it may cause clots to form in the kidneys or ureters, leading to obstruction.

Factors Affecting Cost

Several factors influence the price of aminocaproic acid, including:

• Formulation: The medication is available as oral tablets, an oral solution, and an intravenous injection. The liquid and injectable forms may have different pricing structures than the tablets.
• Generic Availability: Aminocaproic acid is available in generic versions. Generic medications typically cost less than brand-name versions.
• Dosage and Duration: Higher doses or longer treatment cycles will increase the total cost of the prescription.

Insurance and Financial Considerations

Most insurance plans, including Medicare and Medicaid, provide coverage for aminocaproic acid, though the specific copay or coinsurance amount depends on the plan's formulary. Patients should verify coverage with their insurance provider.

For those without insurance or with high out-of-pocket costs, some manufacturers or pharmacies may offer assistance programs or discount cards. Because this medication is sometimes administered in a hospital or clinical setting, the cost may also be included in the overall facility or procedure fees rather than billed as a separate pharmacy prescription.